BioStem Technologies to Announce Third Quarter Results
BioStem Technologies Inc. (OTC: BSEM), renowned for its innovative work in the MedTech sector, is gearing up for an important announcement. The company plans to release its financial results for the third quarter of 2024, marking a key moment for investors and stakeholders. This financial disclosure will occur on an upcoming Tuesday, with a subsequent conference call held at 4:30 PM ET.
Insight into the Upcoming Conference Call
During the conference call, BioStem's CEO Jason Matuszewski and CFO Michael Fortunato will provide a detailed overview of the company’s performance during the quarter. They will discuss not only the financial results but also the strategies moving forward. This is a valuable opportunity for investors to gain insights directly from the leadership team.
How to Participate
Interested participants can join the conference call by following the provided information. The conference ID is 9695874, and a toll-free number for the USA is (800) 715-9871, while international attendees can dial +1 (646) 307-1963. A link to the webcast will also be made available, ensuring that those who can't join live can still access the information later.
About BioStem Technologies, Inc.
BioStem Technologies, Inc. is pioneering advancements in regenerative therapies through the development of placental-derived biologics aimed primarily at advanced wound care. Their proprietary BioREtain processing method exemplifies their commitment to preserving tissue structure and growth factors from perinatal tissues, setting a standard in the industry. The company operates under stringent protocols, accredited by the American Association of Tissue Banks (AATB), underscoring its dedication to quality and safety.
Products and Innovations
The product portfolio features notable brands, including AmnioWrap2™, VENDAJE®, and VENDAJE OPTIC®. Each of these placental allografts is meticulously prepared at the company’s FDA-registered facility in Pompano Beach, Florida. BioStem prides itself on its capacity to manufacture products that not only meet regulatory standards but also significantly enhance patient outcomes.
Quality Management Systems
BioStem Technologies maintains a robust quality management system aligned with Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP). This commitment to quality management ensures that every product released to the market adheres to the highest standards, a crucial factor in maintaining trust among healthcare professionals and patients alike.
Contact Information for BioStem Technologies
For further inquiries, BioStem Technologies can be reached at 954-380-8342 or via email at info@biostemtech.com. Their website, biostemtechnologies.com, also provides additional details about their products and future developments.
Frequently Asked Questions
What are the key highlights of BioStem Technologies?
BioStem Technologies focuses on creating regenerative therapies using placental-derived biologics and is known for its innovative BioREtain processing method.
When will BioStem announce its Q3 2024 results?
The financial results for the third quarter of 2024 will be announced soon, with a conference call scheduled for discussion.
How can I listen to the conference call?
Participants can join the conference call by calling the toll-free number or using the provided webcast link during the scheduled time.
What products does BioStem Technologies offer?
The company offers various products, including AmnioWrap2™, VENDAJE®, and VENDAJE OPTIC®, all designed to support advanced wound care.
What regulatory standards does BioStem adhere to?
BioStem Technologies follows strict guidelines established by the American Association of Tissue Banks (AATB) and is compliant with cGTP and cGMP protocols.
